share_log
Reuters ·  May 9 08:30
Moleculin Biotech Inc - Annamycin Is Advancing Towards Pivotal Aml Study in 2024 and May Qualify for an Accelerated Approval Pathway
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment